Swiss - Delayed Quote CHF

Santhera Pharmaceuticals Holding AG (SANN.SW)

Get top stock picks

15.46 -0.22 (-1.40%)

At close: September 7 at 5:31:59 PM GMT+2

Get top stock picks

Santhera nears cash break-even as AGAMREE gains traction, Edison says

Proactive 20d ago

SANN.SW
-1.40%
S3F0.F

SANN
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

GlobeNewswire 1mo ago

SANN.SW
-1.40%
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy

GlobeNewswire 4mo ago

SANN.SW
-1.40%
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

GlobeNewswire 3mo ago

SANN.SW
-1.40%
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

GlobeNewswire 4mo ago

SANN.SW
-1.40%
4565.T
Santhera Pharmaceuticals CFO on strong FY25 performance & AGAMREE expansion

Proactive 4mo ago

SANN.SW
-1.40%
Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT

Proactive 4mo ago

SANN.SW
-1.40%
AOTI.L

POLB.L
Santhera Publishes Agenda for its Annual General Meeting

GlobeNewswire 4mo ago

SANN.SW
-1.40%
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

GlobeNewswire 4mo ago

SANN.SW
-1.40%
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

GlobeNewswire 3mo ago

SANN.SW
-1.40%
4565.T
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU

GlobeNewswire 4mo ago

SANN.SW
-1.40%
Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue ...

GuruFocus.com 4mo ago

SANN.SW
-1.40%

Yahoo Finance

U.S. markets open in 7h 58m

Santhera Pharmaceuticals Holding AG (SANN.SW)

Santhera nears cash break-even as AGAMREE gains traction, Edison says

Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus

Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025

Santhera Pharmaceuticals CFO on strong FY25 performance & AGAMREE expansion

Santhera Pharmaceuticals, AOTI, Poolbeg Pharma, Solvonis Therapeutics, IBT

Santhera Publishes Agenda for its Annual General Meeting

Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea

Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU

Santhera Pharmaceuticals Holding AG (SPHDF) Full Year 2025 Earnings Call Highlights: Revenue ...